[
    {
        "file_name": "BIOCEPTINC_08_19_2013-EX-10-COLLABORATIONAGREEMENT.txt",
        "perturbation": [
            {
                "type": "Structural Flaws - In Text Contradiction",
                "original_text": "1.15 \"Professional Component\" shall mean the performance of the professional component of the steps of the Assay, which is the interpretation of results (generated in the Technical Component) of an Assay by a pathologist, and is covered by CPT codes from the Professional Fee Schedule with the modifier \"26\".\n\n1.16 \"Technical Component\" shall mean the performance of the technical component of the steps of the Assay, which is the physical performance of the Assay procedure up to the interpretation of results, and is covered by CPT codes from the Professional Fee Schedule without the modifier \"26\", and typically with a modifier \"TC\".",
                "changed_text": "1.15 \"Professional Component\" shall mean either the performance of the technical component of the steps of the Assay, or the interpretation of results (generated in the Technical Component) of an Assay by a pathologist, and may or may not be covered by CPT codes from the Professional Fee Schedule with the modifier \"26\".\n\n1.16 \"Technical Component\" shall mean either the performance of the professional component of the steps of the Assay or the interpretation of results (generated in the Technical Component) of an Assay by a pathologist, and is covered by CPT codes from the Professional Fee Schedule without the modifier \"26\", and typically with a modifier \"TC\".",
                "explanation": "The original text has a clear separation of the Professional component which is the interpretation of the tests, and the technical component. The modified text blurs the definition by stating Professional component can mean either the interpretation of results or the technical component. This introduces contradiction and uncertainty about what each component involves. Therefore, it creates uncertainty in enforcement.",
                "location": "Section 1.15 and 1.16"
            },
            {
                "type": "Structural Flaws - In Text Contradiction",
                "original_text": "8.3 New Technology. In the course of the activities conducted by the parties, Biocept and/or Life Technologies may conceive of inventions or discoveries or create works that constitute intellectual property and may be patentable or registerable as a copyright or other intellectual property right (all of the foregoing, including such intellectual property rights therein, collectively, \"Developments\"). Inventorship of all inventions and discoveries, whether or not patentable, will be determined in accordance with United States patent laws. Authorship of all copyrightable works will be determined in accordance with United States copyright laws. Subject to Section 8.2, as between the parties, Developments will be owned consistent with such determination of inventorship or authorship. To the extent any Development owned by Life Technologies relates directly to the practice of, or constitutes an improvement to, the Assay, Life Technologies hereby grants to Biocept, during the Term of this Agreement, and, except in the case of termination of this Agreement by Life Technologies for Biocept's uncured material breach, after expiration or termination of this Agreement, a non-exclusive, worldwide, royalty-free, fully-paid license, including the right to sublicense, under Life Technologies' Intellectual Property Rights in such Developments, solely to develop, make, have made, use, sell, have sold, offer for sale, import, perform and provide the Assay. To the extent any Development owned by Biocept relates directly to the practice of, or constitutes an improvement to, the Assay, Biocept hereby grants to Life Technologies, during the Term of this Agreement, a non-exclusive license under Biocept's Intellectual Property Rights in such Development, solely to promote the Assay in the Territory and to perform the Professional Component of the Assay sold by the parties in the Territory, in accordance with the terms of this Agreement.",
                "changed_text": "8.3 New Technology. In the course of the activities conducted by the parties, Biocept and/or Life Technologies may conceive of inventions or discoveries or create works that constitute intellectual property and may be patentable or registerable as a copyright or other intellectual property right (all of the foregoing, including such intellectual property rights therein, collectively, \"Developments\"). Inventorship of all inventions and discoveries, whether or not patentable, will be determined in accordance with United States patent laws. Authorship of all copyrightable works will be determined in accordance with United States copyright laws. Subject to Section 8.2, as between the parties, Developments will be owned as decided mutually. To the extent any Development owned by Life Technologies relates directly to the practice of, or constitutes an improvement to, the Assay, Life Technologies may or may not grant Biocept, during the Term of this Agreement, and, except in the case of termination of this Agreement by Life Technologies for Biocept's uncured material breach, after expiration or termination of this Agreement, a non-exclusive, worldwide, royalty-free, fully-paid license, including the right to sublicense, under Life Technologies' Intellectual Property Rights in such Developments, solely to develop, make, have made, use, sell, have sold, offer for sale, import, perform and provide the Assay. To the extent any Development owned by Biocept relates directly to the practice of, or constitutes an improvement to, the Assay, Biocept may or may not grant Life Technologies, during the Term of this Agreement, a non-exclusive license under Biocept's Intellectual Property Rights in such Development, solely to promote the Assay in the Territory and to perform the Professional Component of the Assay sold by the parties in the Territory, in accordance with the terms of this Agreement.",
                "explanation": "The original text states that Developments will be owned consistent with such determination of inventorship or authorship. The modified text now states that developments will be owned as decided mutually. This creates confusion on how developments on intellectual property will be handled. Also, the original text guarantees that Licences are granted to both parties. The modified text removes the guarantee by saying they may or may not be granted. This creates uncertainty in enforcement.",
                "location": "Section 8.3"
            },
            {
                "type": "Structural Flaws - In Text Contradiction",
                "original_text": "9.5 Limitation of Liability. NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT OR ANY LICENSE GRANTED HEREUNDER; provided, however, that this Section shall neither (a) apply to any liability for damages arising from breach of any obligations of confidentiality under Article 10, nor (b) limit the indemnification obligations of the parties arising under Article 12 of this Agreement.",
                "changed_text": "9.5 Limitation of Liability. NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT OR ANY LICENSE GRANTED HEREUNDER; provided, however, that this Section may apply to any liability for damages arising from breach of any obligations of confidentiality under Article 10, nor may limit the indemnification obligations of the parties arising under Article 12 of this Agreement.",
                "explanation": "The original text clearly states the limitation of liability does not apply to breaches of confidentiality or indemnification obligations. The modified text is now uncertain by stating it \"may\" apply and \"may\" limit the indemnification obligations. Therefore, it creates uncertainty in enforcement.",
                "location": "Section 9.5"
            }
        ]
    }
]